Cosmo Pharmaceuticals NV 2023 AR2
The report highlights Cosmo Pharmaceuticals' financial and operational performance for the fiscal year 2023, emphasizing its expanded artificial intelligence partnership with Medtronic. Financially, the company recorded total revenue of €92.8 million and generated €33.6 million in cash from operating activities, while successfully redeeming its €175 million convertible bonds. On the ESG front, Cosmo achieved ISO 14001 certification for its environmental management system in early 2024 and reduced its water consumption by 9.1% in 2023. Additionally, the company maintained its commitment to diversity, with women representing 37% of its total workforce of 325 employees.
Company: Cosmo Pharmaceuticals NV
Sector: Manufacturing
Country: Ireland
Year: 2023
Type: AR2
Pages: 160
Back to company
Cosmo Pharmaceuticals NV
Annual Report And Accounts
The report highlights Cosmo Pharmaceuticals' financial and operational performance for the fiscal year 2023, emphasizing its expanded artificial intelligence partnership with Medtronic. Financially, the company recorded total revenue of €92.8 million and generated €33.6 million in cash from operating activities, while successfully redeeming its €175 million convertible bonds. On the ESG front, Cosmo achieved ISO 14001 certification for its environmental management system in early 2024 and reduced its water consumption by 9.1% in 2023. Additionally, the company maintained its commitment to diversity, with women representing 37% of its total workforce of 325 employees.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Women in Management
Employees